re ENTA slide deck Slide 18 discussing the pediatric RSV data has a one liner about the recent post hoc analysis that was presented last month: ReSViNET: Reduced the time to complete symptom resolution Here is a link to that presentation for anyone who was not aware of this data: https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-presents-new-data-zelicapavir-its-n